Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies - Spector, N L; Xia, W; Burris, H (Journal of Clinical Oncology, 2005)